This open-label extension of the SERAPHIN trial evaluated the long-term safety and tolerability of a small daily dose of the endothelin receptor antagonist against pulmonary arterial hypertension (PAH) among patients from the original study.
Safety and survival data from the SERAPHIN open-label (OL) long-term multicenter single-arm noncomparative trial of 10-mg daily macitentan show the endothelin receptor antagonist is safe and tolerable over the longer term among patients who have pulmonary arterial hypertension (PAH).
These findings were published recently in Advances in Therapy, and they echo findings from SERAPHIN OL’s predecessor, the SERAPHIN trial, which investigated the ability of 10-mg daily macitentan to reduce morbidity and mortality in PAH. All patients (N = 550) had been participants in the first trial, and they all received the same dosage in the extension study. In addition, SERAPHIN OL evaluated the drug’s safety in overlapping sets: all patients (OL safety set) and patients first randomized to once-daily macitentan 10 mg (vs once-daily 3-mg macitentan or placebo) in the SERAPHIN study (n = 242; long-term safety/survival set).
“Long-term data from patients with PAH are sparse,” the authors wrote. “The SERAPHIN OL study provides data on long-term safety, tolerability and survival for patients with PAH treated with macitentan.”
Overall, 50.5% of the OL safety set completed treatment. The mean (SD) age of these patients was 47.7 (15.7) years, 80.0% were female, and most had World Health Organization functional class II (45.1%) or III (31.5%) disease and were receiving background PAH therapy (67.5%). Including the safety follow-up period of 28 days, this patient group also had a median macitentan exposure of 40.1 (range, 0.1-130.5) months, for 2074.7 patient-years. Approximately one-third of patients (31.3%) received 10-mg macitentan for at least 5 years.
The most common adverse effects (AEs) reported by patients were PAH worsening (28.5%) and upper respiratory tract infection (23.1%). Among the 11.3% with an AE that led to treatment discontinuation, the most common were PAH worsening (2.4%) and right ventricular failure (1.8%). Further, among the 31.8% who had died by the end of the follow-up period, PAH worsening was the most common reason (10.5%).
The incident rate of increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to 3 times the upper limit of normal (ULN) was 2.2 per 100 patient-years.
For the long-term survival set, the patients had a median macitentan exposure of 54.7 (range, 0.1-141.3) months, for 1151.0 patient-years. The most common was at least 5 years in 43%. In addition, 96.2% of patients were exposed to macitentan “without or prior to the addition of any new PAH therapies during the study,” the authors noted, and among those who started a concomitant PAH therapy (6.2%), a phosphodiesterase 5 inhibitor was the most common (3.3%).
Among this cohort, PAH worsening was again the most common AE (35.5%) and peripheral edema the second most common (26.0%). Sixteen percent had an AE that necessitated treatment discontinuation. Again, PAH worsening and right ventricular failure were the most common reasons, at 2.1% and 1.7%, respectively, for treatment discontinuation, and PAH the most common cause of death (9.1%) among the 32.2% of the long-term safety/survival who had died by the end of the treatment period.
In addition, the ALT/AST increase incident rate was close to equal vs the OL safety set, at 1.9 per 100 patient-years.
Kaplan-Meier estimates for survival show that more than half of the patients remained alive at the 9-year mark. These results show 95.0%, 84.0%, 73.3%, 62.6%, and 52.7% were alive at 1, 3, 5, 7, and 9 years, respectively.
“The 2 analysis sets provided complementary data on the safety of macitentan in PAH and showed that macitentan 10 mg was well tolerated by PAH patients,” the investigators concluded. “As safety and tolerability were consistent between the 2 sets, these results provide evidence on the safety of macitentan, including in a patient population with more advanced disease.”
Reference
Souza R, Delcroix M, Galié N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374-4390. doi:10.1007/s12325-022-02199-x
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More